Öz
Objectives: Prostate specific antigen (PSA) is the most commonly used marker
for prostate cancer. PSA-based screening has reduced disease-specific mortality.
However, PSA is not specific for prostate cancer, but is specific for prostate tissue and
increases in benign conditions.
Material and Methods: In our study, 63 patients with PSA values of 1.5 ng / ml or less
were evaluated retrospectively with 636 patients who underwent prostate sampling
because of the suspicion of prostate cancer.
Results: In our study, 34.9% prostate cancer and 4.1% ASAP were detected below
1.5 ng / ml of PSA. Our results suggest that a significant number of cancers were
detected below 1.5 ng / ml of PSA.
Conclusion: A significant number of prostate cancers are found below 1.5 ng / ml
PSA. The lack of a PSA value that we can say without prostate cancer leads to the
need for a low cost and reliable marker.
Anahtar Kelimeler
Kaynakça
- Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, et al. Early Stage Prostate Cancer An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016; 96: 116-120.
Öz
Kaynakça
- Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, et al. Early Stage Prostate Cancer An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016; 96: 116-120.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Articles |
| Yazarlar | |
| Yayımlanma Tarihi | 28 Eylül 2018 |
| Gönderilme Tarihi | 16 Temmuz 2017 |
| Yayımlandığı Sayı | Yıl 2018 Cilt: 8 Sayı: 3 |
Kaynak Göster
